Uncovering the Roles of MicroRNAs in Major Depressive Disorder: From Candidate Diagnostic Biomarkers to Treatment Response Indicators

Major depressive disorder (MDD) is a recurrent debilitating illness that represents a major health burden due to its increasing worldwide prevalence, unclear pathological mechanism, nonresponsive treatment, and lack of reliable and specific diagnostic biomarkers. Recently, microRNA species (miRs) ha...

Full description

Saved in:
Bibliographic Details
Published inLife (Basel, Switzerland) Vol. 11; no. 10; p. 1073
Main Authors Homorogan, Claudia, Nitusca, Diana, Seclaman, Edward, Enatescu, Virgil, Marian, Catalin
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 11.10.2021
MDPI
Subjects
Alzheimer's disease
antidepressant treatment
Antidepressants
Biomarkers
Brain research
Diagnostic systems
Gene expression
Health care
Human subjects
Indicators
major depressive disorder
Mental depression
Mental disorders
MicroRNAs
miRNA
mRNA stability
Nervous system
Neurobiology
Neurosciences
Pathophysiology
Patients
Plasma
Post-transcription
Review
Ribonucleic acid
RNA
Online AccessGet full text

Cover

More Information
Summary:Major depressive disorder (MDD) is a recurrent debilitating illness that represents a major health burden due to its increasing worldwide prevalence, unclear pathological mechanism, nonresponsive treatment, and lack of reliable and specific diagnostic biomarkers. Recently, microRNA species (miRs) have gained particular interest because they have the ability to post-transcriptionally regulate gene expression by modulating mRNA stability and translation in a cohesive fashion. By regulating entire genetic circuitries, miRs have been shown to have dysregulated expression levels in blood samples from MDD patients, when compared to healthy subjects. In addition, antidepressant treatment (AD) also appears to alter the expression pattern of several miRs. Therefore, we critically and systematically reviewed herein the studies assessing the potential biomarker role of several candidate miRs for MDD, as well as treatment response monitoring indicators, in order to enrich the current knowledge and facilitate possible diagnostic biomarker development for MDD, which could aid in reducing both patients’ burden and open novel avenues toward a better understanding of MDD neurobiology.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2075-1729
2075-1729
DOI:10.3390/life11101073